JP2004509073A - 新規なｃ−４置換レチノイド - Google Patents

新規なｃ−４置換レチノイド Download PDF

Info

Publication number
JP2004509073A
JP2004509073A JP2002508369A JP2002508369A JP2004509073A JP 2004509073 A JP2004509073 A JP 2004509073A JP 2002508369 A JP2002508369 A JP 2002508369A JP 2002508369 A JP2002508369 A JP 2002508369A JP 2004509073 A JP2004509073 A JP 2004509073A
Authority
JP
Japan
Prior art keywords
group
compound
atra
pharmaceutical composition
retinoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002508369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509073A5 (https=
Inventor
ヌジャル，　ビンセント　シー．　オー．
ブロディー，　アンジェラ　エム．　エイチ．
ナーン，　イボ　ピー．
Original Assignee
ユニバーシティ・オブ・メリーランド，　ボルティモア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ・オブ・メリーランド，　ボルティモア filed Critical ユニバーシティ・オブ・メリーランド，　ボルティモア
Publication of JP2004509073A publication Critical patent/JP2004509073A/ja
Publication of JP2004509073A5 publication Critical patent/JP2004509073A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D331/00—Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom
    • C07D331/02—Three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2002508369A 2000-07-11 2001-07-11 新規なｃ−４置換レチノイド Pending JP2004509073A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21746500P 2000-07-11 2000-07-11
PCT/US2001/016524 WO2002003912A2 (en) 2000-07-11 2001-07-11 Novel c-4 substituted retinoids

Publications (2)

Publication Number Publication Date
JP2004509073A true JP2004509073A (ja) 2004-03-25
JP2004509073A5 JP2004509073A5 (https=) 2008-09-04

Family

ID=22811193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002508369A Pending JP2004509073A (ja) 2000-07-11 2001-07-11 新規なｃ−４置換レチノイド

Country Status (6)

Country Link
US (2) US7265143B2 (https=)
EP (1) EP1305274A4 (https=)
JP (1) JP2004509073A (https=)
AU (2) AU2001271265B2 (https=)
CA (1) CA2415169C (https=)
WO (1) WO2002003912A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519297A (ja) * 2005-12-14 2009-05-14 ピエール、ファブレ、デルモ‐コスメティーク ポリ不飽和化合物の美白化剤としての使用
JP2009519298A (ja) * 2005-12-14 2009-05-14 ピエール、ファブレ、デルモ‐コスメティーク 新規なポリ不飽和化合物、これらの化合物の製造方法、およびこれらの化合物を含む組成物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242689A1 (en) * 1999-08-26 2004-12-02 Parks L. Dean Method of treating benign prostatic hyperplasia and other benign prostate conditions
US20050107352A1 (en) * 1999-08-26 2005-05-19 Parks L. D. Method of treating benign prostatic hyperplasia
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
US20100184812A1 (en) * 2007-06-06 2010-07-22 University Of Maryland, Baltimore Mutual prodrugs and methods to treat cancer
WO2010036404A2 (en) * 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
WO2011016863A2 (en) * 2009-08-05 2011-02-10 Angion Biomedica Corp. Methods and uses of cytochrome p450 inhibitors
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
CN102985420B (zh) 2010-06-01 2017-07-04 安吉翁生物医药有限公司 细胞色素p450抑制剂及其用途
WO2013028771A1 (en) 2011-08-23 2013-02-28 Leong Hwei Xian Reversing intestinal inflammation by inhibiting retinoic acid metabolism
WO2014093960A1 (en) * 2012-12-16 2014-06-19 Angion Biomedica Corp. Compositions and methods for treating disease
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
WO2016081589A2 (en) 2014-11-20 2016-05-26 University Of Maryland, Baltimore 13-cis-ramba retinamides that degrade mnks for treating cancer
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
CN109675256B (zh) * 2019-03-02 2023-05-23 哈尔滨理工大学 一种内齿啮合式乳腺癌术后康复训练装置及使用方法
US12528776B2 (en) * 2019-12-19 2026-01-20 University Of Maryland, Baltimore Composition and method for treating dermatological disorders using retinamides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54135752A (en) * 1978-04-12 1979-10-22 Hoffmann La Roche Nonatetraene acid derivative
US5808120A (en) * 1995-08-22 1998-09-15 Wisconsin Alumni Research Foundation Method of synthesis of retinoic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124083A (en) * 1990-08-30 1992-06-23 Southern Research Institute 3-substituted and 3,3-disubstituted 4-oxoretinoic acids and their esters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54135752A (en) * 1978-04-12 1979-10-22 Hoffmann La Roche Nonatetraene acid derivative
US5808120A (en) * 1995-08-22 1998-09-15 Wisconsin Alumni Research Foundation Method of synthesis of retinoic acid

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519297A (ja) * 2005-12-14 2009-05-14 ピエール、ファブレ、デルモ‐コスメティーク ポリ不飽和化合物の美白化剤としての使用
JP2009519298A (ja) * 2005-12-14 2009-05-14 ピエール、ファブレ、デルモ‐コスメティーク 新規なポリ不飽和化合物、これらの化合物の製造方法、およびこれらの化合物を含む組成物
US8420610B2 (en) 2005-12-14 2013-04-16 Pierre Fabre Dermo-Cosmetique Polyunsaturated compounds, method for preparing same and compositions containing the same
US8481011B2 (en) 2005-12-14 2013-07-09 Pierre Fabre Dermo-Cosmetique Use of polyunsaturated compounds as whitening agents

Also Published As

Publication number Publication date
CA2415169A1 (en) 2002-01-17
AU2001271265B2 (en) 2005-01-06
EP1305274A4 (en) 2005-10-12
WO2002003912A2 (en) 2002-01-17
US20030162823A1 (en) 2003-08-28
US20120122908A1 (en) 2012-05-17
EP1305274A2 (en) 2003-05-02
CA2415169C (en) 2010-06-01
US7265143B2 (en) 2007-09-04
AU7126501A (en) 2002-01-21
WO2002003912A3 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
US20120122908A1 (en) Novel C-4 Substituted Retinoids
JP6559092B2 (ja) レソルビン：治療処置用のバイオテンプレート
Rowlands et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17. alpha.-Hydroxylase/C17, 20-lyase (Cytochrome P45017. alpha.) with resistance to esterase hydrolysis
Bossche et al. Aromatase inhibitors—mechanisms for non-steroidal inhibitors
US5763432A (en) Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use
AU2001271265A1 (en) Novel C-4 substituted retinoids
Patel et al. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice
SK140494A3 (en) Inhibitors of testosterone 5-alpha-reductase activity
FR2584725A1 (fr) Androsta-1,4-diene-3,17-diones substituees, leur procede de fabrication et medicaments les contenant
CN105592888A (zh) 用于治疗疾病的kdm1a抑制剂
EP2891649A1 (en) Prolylhydroxylase inhibitors and methods of use
Kuranov et al. Exploring bulky natural and natural-like periphery in the design of p-(benzyloxy) phenylpropionic acid agonists of free fatty acid receptor 1 (GPR40)
EP3634975B1 (en) 17-oximes of 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-ones for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
JP3226919B2 (ja) 不飽和の１７β―置換―３―カルボキシステロイド
WO2016144871A1 (en) Altering steroid metabolism for treatment of steroid-dependent disease
Hartmann et al. Pyridyl-substituted tetrahydrocyclopropa [a] naphthalenes: highly active and selective inhibitors of P450 arom
JP5950413B2 (ja) パーシャルアゴニスト活性を持つ新規ビタミンｄ受容体モジュレーター
Auvray et al. MR 20492 and MR 20494: two indolizinone derivatives that strongly inhibit human aromatase
EP2556082B1 (en) Substituted androst-4-ene diones
US20100184812A1 (en) Mutual prodrugs and methods to treat cancer
US20180118707A1 (en) Beta-naphthoisoflavones, compositions containing, and uses of, same
CN115087487A (zh) 使用维甲酰胺治疗皮肤病的组合物和方法
LU86921A1 (fr) Derives methyleniques d'androst-4-ene-3,17-diones et procede pour leur preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080709

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111012